SENZA Stock Overview
Provides non-animal tests for assessing a substance’s allergenicity. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SenzaGen AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 7.00 |
| 52 Week High | SEK 9.80 |
| 52 Week Low | SEK 5.46 |
| Beta | 0.45 |
| 11 Month Change | -6.67% |
| 3 Month Change | -6.67% |
| 1 Year Change | -2.78% |
| 33 Year Change | -43.78% |
| 5 Year Change | -66.35% |
| Change since IPO | -83.83% |
Recent News & Updates
Recent updates
Shareholders Will Probably Hold Off On Increasing SenzaGen AB's (STO:SENZA) CEO Compensation For The Time Being
May 09
We're Not Very Worried About SenzaGen's (STO:SENZA) Cash Burn Rate
Nov 28We're Hopeful That SenzaGen (STO:SENZA) Will Use Its Cash Wisely
Jul 30Companies Like SenzaGen (STO:SENZA) Are In A Position To Invest In Growth
Apr 16Here's Why We're Not Too Worried About SenzaGen's (STO:SENZA) Cash Burn Situation
Jan 01Shareholder Returns
| SENZA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.8% | -5.8% | -2.1% |
| 1Y | -2.8% | 14.3% | 10.8% |
Return vs Industry: SENZA underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: SENZA underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| SENZA volatility | |
|---|---|
| SENZA Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: SENZA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SENZA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 33 | Peter Nahlstedt | senzagen.com |
SenzaGen AB provides non-animal tests for assessing a substance’s allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation, corrosion, sensitization, and absorption testing services, as well as phototoxicity services.
SenzaGen AB Fundamentals Summary
| SENZA fundamental statistics | |
|---|---|
| Market cap | SEK 206.53m |
| Earnings (TTM) | -SEK 18.04m |
| Revenue (TTM) | SEK 58.43m |
3.5x
P/S Ratio-11.5x
P/E RatioIs SENZA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SENZA income statement (TTM) | |
|---|---|
| Revenue | SEK 58.43m |
| Cost of Revenue | SEK 16.52m |
| Gross Profit | SEK 41.91m |
| Other Expenses | SEK 59.95m |
| Earnings | -SEK 18.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 71.73% |
| Net Profit Margin | -30.87% |
| Debt/Equity Ratio | 2.3% |
How did SENZA perform over the long term?
See historical performance and comparison